Neurocrine Biosciences retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $0.081B, a 126.61% decline year-over-year.
Neurocrine Biosciences retained earnings (accumulated deficit) for 2023 were $-0.157B, a 61.38% decline from 2022.
Neurocrine Biosciences retained earnings (accumulated deficit) for 2022 were $-0.407B, a 36.02% decline from 2021.
Neurocrine Biosciences retained earnings (accumulated deficit) for 2021 were $-0.636B, a 12.35% decline from 2020.